Versameb AG is a biopharmaceutical company developing next-generation RNA-based therapeutics. The company’s unique proprietary technology platform generates molecules optimized for improved secretion and modulation of several therapeutic targets. The company has just announced a seed round of CHF 6 million that is intended for the advancement of the lead asset towards the clinic by the end of 2021, in addition to progressing other applications in therapeutic areas of high-unmet medical need.
Versameb also welcomes Dr. Klaas P. Zuideveld as Chief Development Officer. Prior to Versameb he was Vice President of Partnerships at Caris Life Sciences, and before he held several leadership roles in drug development and consulted for Pharsight (acquired by Certara), F. Hoffmann-La Roche, Mosaic Biomedicals (acquired by Northern Biologics) and Therachon (acquired by Pfizer).
The full press release can be found here.